Cdk2 inhibitors
US-2023159535-A1 · May 25, 2023 · US
CDK2 inhibitors
US11970498B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11970498-B2 |
| Application number | US-202318166178-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 8, 2023 |
| Priority date | Jun 28, 2021 |
| Publication date | Apr 30, 2024 |
| Grant date | Apr 30, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure provides a compound represented by structural Formula (I):or a pharmaceutically acceptable salt thereof useful for treating a cancer.
First claim
Opening claim text (preview).
The invention claimed is: 1. A pharmaceutically acceptable salt of a compound selected from the group consisting of: 2. The salt of claim 1 , wherein the compound is 3. The salt of claim 1 , wherein the compound is 4. The salt of claim 1 , wherein the compound is 5. The salt of claim 1 , wherein the compound is 6. The salt of claim 1 , wherein the compound is selected from the group consisting of: 7. The salt of claim 1 , wherein the compound is 8. The salt of claim 1 , wherein the compound is 9. The salt of claim 1 , wherein the compound is 10. The salt of claim 1 , wherein the compound is 11. The salt of claim 1 , wherein the compound is 12. The salt of claim 1 , wherein the compound is 13. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a salt of claim 1 . 14. A compound selected from the group consisting of: 15. The compound of claim 14 , wherein the compound is 16. The compound of claim 14 , wherein the compound is 17. The compound of claim 14 , wherein the compound is 18. The compound of claim 14 , wherein the compound is 19. The compound of claim 14 selected from the group consisting of: 20. The compound of claim 14 , wherein the compound is 21. The compound of claim 14 , wherein the compound is 22. The compound of claim 14 , wherein the compound is 23. The compound of claim 14 , wherein the compound is 24. The compound of claim 14 , wherein the compound is 25. The compound of claim 14 , wherein the compound is 26. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of claim 14 .
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
not condensed and containing further heterocyclic rings · CPC title
- A61K31/4985Primary
Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems · CPC title
- C07D487/04Primary
Ortho-condensed systems · CPC title
Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00 · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11970498B2 cover?
- The present disclosure provides a compound represented by structural Formula (I):or a pharmaceutically acceptable salt thereof useful for treating a cancer.
- Who is the assignee on this patent?
- Blueprint Medicines Corp
- What technology area does this patent fall under?
- Primary CPC classification A61K31/4985. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Apr 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).